HROW | Harrow Health, Inc.

Index- P/E- EPS (ttm)-0.65 Insider Own0.30% Shs Outstand30.29M Perf Week3.58%
Market Cap617.73M Forward P/E23.34 EPS next Y0.87 Insider Trans- Shs Float25.25M Perf Month-26.94%
Income-18.30M PEG- EPS next Q-0.06 Inst Own52.80% Short Float / Ratio11.44% / 6.31 Perf Quarter14.85%
Sales92.60M P/S6.67 EPS this Y25.70% Inst Trans-5.23% Short Interest2.89M Perf Half Y67.58%
Book/sh0.72 P/B28.14 EPS next Y302.30% ROA-12.80% Target Price37.13 Perf Year169.77%
Cash/sh0.88 P/C23.05 EPS next 5Y15.00% ROE-129.60% 52W Range6.00 - 28.25 Perf YTD37.26%
Dividend- P/FCF- EPS past 5Y3.00% ROI1.40% 52W High-28.28% Beta0.20
Dividend %- Quick Ratio2.40 Sales past 5Y27.00% Gross Margin70.10% 52W Low237.67% ATR1.41
Employees217 Current Ratio2.90 Sales Q/Q18.10% Oper. Margin-4.90% RSI (14)42.91 Volatility5.30% 7.42%
OptionableYes Debt/Eq0.00 EPS Q/Q-144.90% Profit Margin-19.80% Rel Volume0.60 Prev Close20.51
ShortableYes LT Debt/Eq7.71 EarningsMay 11 AMC Payout- Avg Volume458.06K Price20.26
Recom1.70 SMA20-4.63% SMA50-11.44% SMA20028.76% Volume274,285 Change-1.22%
Date Action Analyst Rating Change Price Target Change
Sep-08-22Resumed B. Riley Securities Buy $17
Oct-14-21Resumed B. Riley Securities Buy $16
Sep-24-21Initiated Aegis Capital Buy $15
Jul-02-21Initiated Ladenburg Thalmann Buy $14.25
May-17-23 08:00AM
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
05:15PM Loading…
May-11-23 05:15PM
May-08-23 12:07PM
May-04-23 08:00AM
May-03-23 06:44AM
May-02-23 04:42PM
08:50AM Loading…
May-01-23 08:50AM
Apr-28-23 06:00PM
Apr-27-23 08:05AM
Apr-24-23 08:43AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
09:34AM Loading…
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Feb-16-23 06:42AM
Feb-15-23 07:00AM
Feb-03-23 08:50AM
Feb-02-23 06:30AM
Jan-23-23 07:00AM
Jan-21-23 07:33AM
Jan-18-23 08:50AM
Jan-05-23 07:00AM
Dec-25-22 07:24AM
Dec-21-22 09:21AM
Dec-16-22 07:00AM
Dec-14-22 03:24PM
Nov-30-22 08:00AM
Nov-16-22 05:06AM
Nov-14-22 04:05PM
Nov-10-22 08:00AM
Oct-28-22 08:00AM
Oct-27-22 08:00AM
Oct-13-22 09:35AM
Oct-06-22 03:23PM
Oct-05-22 05:35PM
Sep-29-22 07:00AM
Sep-28-22 07:09AM
Sep-27-22 01:50PM
Sep-21-22 06:01PM
Aug-27-22 06:37PM
Aug-11-22 08:00AM
Aug-09-22 04:45PM
Jul-27-22 07:00AM
Jul-16-22 08:08AM
Jun-24-22 08:00AM
May-30-22 06:12AM
May-06-22 09:01AM
May-05-22 04:01PM
May-04-22 08:00AM
Apr-22-22 08:00AM
Apr-20-22 07:00AM
Mar-31-22 07:00AM
Mar-10-22 04:01PM
Feb-24-22 08:00AM
Feb-22-22 07:00AM
Feb-15-22 07:00AM
Feb-10-22 04:50PM
Feb-08-22 08:00AM
Feb-06-22 08:36AM
Jan-10-22 06:45AM
Jan-04-22 08:00AM
Dec-30-21 10:24AM
Dec-20-21 07:00AM
Dec-13-21 08:00AM
Dec-07-21 04:32PM
Dec-06-21 11:54AM
Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAUM MARK LChief Executive OfficerApr 03Option Exercise8.99180,0001,618,2001,664,962Apr 04 07:54 PM
BOLL ANDREW R.Chief Financial OfficerMar 31Option Exercise6.0090,000540,000358,461Apr 04 07:50 PM
BAUM MARK LChief Executive OfficerDec 22Buy13.3925,000334,7501,432,141Dec 23 07:03 AM
BOLL ANDREW R.Chief Financial OfficerDec 22Buy13.542,50033,850255,063Dec 23 07:02 AM
Van Horn R. LawrenceDirectorDec 22Buy13.421,86024,9611,860Dec 23 07:00 AM
Makary Martin A.DirectorDec 21Buy13.3725,000334,25025,000Dec 23 07:01 AM
Opaleye Management Inc.10% OwnerDec 14Buy10.52431,1834,536,0453,600,000Dec 14 04:05 PM
LINDSTROM RICHARD L MDDirectorSep 30Sale12.6240,000504,80026,100Oct 03 06:02 PM
Opaleye Management Inc.10% OwnerSep 28Buy9.7711,085108,3543,185,000Sep 30 06:15 AM